An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis

Trial Profile

An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs MIV 711 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Medivir AB
  • Most Recent Events

    • 25 Jul 2017 According to a Medivir AB media release, data from this study will be available in the first quarter of 2018.
    • 09 Jun 2017 The independent Data Monitoring Committee (DMC) has recommended continuation of the extension study based on a review of the accumulated safety data according to a Medivir AB media release.
    • 09 Jun 2017 Status changed from recruiting to active, no longer recruiting according to a Medivir AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top